Physician profile
Robert W Pattillo
NPI 1821077355
$4,162.12
in general payments reported to CMS, 2019-2025
24 companies · $435 in 2025
The $435 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $209 · 2021: $938 · 2022: $696 · 2023: $791 · 2024: $565 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,791.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $1,006.06 | 2021-2025 | Optimizer, Optimizer |
| Abbott Laboratories | $577.21 | 2019-2025 | Jot Dx, Amplatzer Amulet, Aveir |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $472.52 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $378.72 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $232.27 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $210.24 | 2019-2025 | |
| Amgen INC. | $166.12 | 2019-2023 | Repatha |
| Atricure, INC. | $165.56 | 2022 | |
| Esperion Therapeutics, INC. | $149.55 | 2021-2022 | |
| Zoll Respicardia, INC. | $143.49 | 2021 | |
| Inari Medical, INC. | $131.82 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pfizer INC. | $117.69 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $65.21 | 2019-2023 | Camzyos, Eliquis |
| W. L. Gore & Associates, INC. | $59.92 | 2022 | |
| Merck Sharp & Dohme LLC | $45.50 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $44.17 | 2024 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $42.81 | 2019 | |
| Novo Nordisk INC | $28.31 | 2024 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $27.74 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $25.97 | 2019 | |
| Philips North America LLC | $19.92 | 2025 | Event |
| Edwards Lifesciences Corporation | $19.80 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $16.58 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pattillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.